Study of the Immunogenicity and Safety of a Quadrivalent Influenza Vaccine (VAX2012Q) in Adults 18-64 Years

Status unconfirmed · Phase 2

Conditions studied: Influenza

In brief

This is a multi-center, randomized, double-blind, active comparator controlled study in which up to 450 healthy adults age 18-64 years will be administered either one of two dose levels of VAX2012Q or a licensed quadrivalent influenza vaccine. The subjects will be randomized at a 1:1:1 ratio.

Key facts

Study ID

NCT02434276

Run by

VaxInnate Corporation

People needed

450

Starts

2015-05-01

Expected to finish

2016-06-01

Last updated by the study team

2015-06-26

Who can join

Age: 18 and older, up to 64. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Males and females, 18-64 years of age.
• Females must be:
• Surgically sterilized
• Post menopausal:
• 12 months of spontaneous amenorrhea or
• 6 months of spontaneous amenorrhea with serum follicle-stimulating hormone (FSH) levels > 40 milli-International Units (mIU)/ml or
• 6 weeks postsurgical bilateral oophorectomy
• Those of childbearing potential must have a negative pre-treatment serum pregnancy test followed by a confirmatory urine pregnancy test immediately prior to vaccination and must agree to use a reliable form of contraception for at least 21 days post vaccination including contraceptives, intrauterine device, double-barrier method.
• In good health as determined by medical history, physical exam, laboratory assessments and the clinical judgment of the Principal Investigator.
• Must sign informed consent indicating understanding of the purpose of and procedures required for the study and willingness to participate.

You may not qualify if…

• Within 6 months preceding the administration of the study vaccine, receiving any licensed or investigational vaccine.
• Within 30 days preceding the administration of the study vaccine, receiving any investigational drug.
• Excessive chronic alcohol use within the last 5 years.
• History of drug abuse, other than recreational cannabis use, within the last 5 years that could affect the subject's participation in the study.
• Significant psychiatric illness within the last 12 months which would interfere with the study.
• A chronic illness that is not medically stable, receiving a concomitant therapy in which the medication dose has not been stable for at least 3 months prior to immunization or has any other condition that could interfere with the study.
• Clinically significant abnormal liver function tests at screening: alanine transaminase (ALT) or aspartate aminotransferase (AST) >2.5 Upper Limit of Normal (ULN).
• Total bilirubin > 1.5 ULN if ALT or AST > ULN or total bilirubin > 2 ULN with ALT and AST within normal range .
• Creatinine >1.7mg/dL, Hemoglobin < 11g/dL for females; <12.5 g/dL for males, white blood cells (WBC) <2500cell/mm3 or > 15,000cell/mm3, Platelet Count <125,000cell/mm3
• Positive serology for HBSAg, hepatitis C virus (HCV) or HIV
• Have cancer or have received treatment for cancer within three years, excluding in situ cervical carcinoma or basal /squamous cell carcinoma of the skin at other than the vaccination site.
• Any autoimmune disease.
• Presently receiving or having a recent history of receiving (≤ six months) any medication or therapeutic modality that affects the immune system or a drug known to be frequently associated with significant major organ toxicity or system corticosteroids (oral or injectable).
• History of severe allergic reaction after previous vaccinations or hypersensitivity to any seasonal influenza vaccine component.
• Allergic to egg or egg products.
• History of Guillain-Barré Syndrome.
• Receipt of blood or blood products 8 weeks prior to vaccination or planned administration during the three week study period following vaccination
• Donation of blood or blood products within 4 weeks prior to vaccination or during the 4 week study period following vaccination.
• Acute disease within 72 hours prior to vaccination.
• An oral temperature >100.4°F (38°C) on the day of vaccination
• Body Mass Index >40.
• Known bleeding disorders or receiving prescribed oral or parenteral anticoagulants.
• Any other condition or circumstance which, in the opinion of the Principal Investigator, poses an unacceptable risk for participation in the study or could interfere with study evaluations.

Where it is running

• Optimal Research — Huntsville, Alabama, United States
• Optimal Research — San Diego, California, United States
• Optimal Research — Melbourne, Florida, United States
• Optimal Research — Peoria, Illinois, United States
• Optimal Research — Mishawaka, Indiana, United States
• Optimal Research — Rockville, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.